Indo Us Biotech Limited — Important, 11-02-2025: Financial Result Updates

**Indo-US Bio-Tech Limited Financial Summary**

Indo-US Bio-Tech Limited reported consolidated financial results for the quarter ended 31st December 2024, showcasing revenue from operations of ₹23,563.5 crore, reflecting a growth of 6.4% compared to ₹22,113.7 crore in the same period last year. This growth is attributed to increased market demand and strategic market expansion efforts.

The company posted a net profit of ₹505.5 crore, showing a substantial increase from ₹435.95 crore year-over-year. The Earnings Per Share (EPS) improved to ₹25.2, up from ₹21.6, highlighting profitability drivers such as effective cost management and operational efficiencies.

Operational costs increased moderately, totaling ₹1,856.5 crore, but the company successfully managed most expenses, leading to a competitive profit margin. The balance sheet remains robust, supported by timely inventory management and effective debt controls, enhancing the overall financial health.

Strategically, the company is focusing on maintaining cost efficiency and exploring expansion opportunities within its product segment. Market sentiment appears optimistic given the positive revenue trajectory and solid profit margins.

Investor Insight: Given the consistent growth in revenue and profit, alongside strong cost management, a favorable outlook suggests a potential buy for investors looking for growth in the agri-tech sector.